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Off-Label Prescription of Genetically Modified
Organism Medicines in Europe:
Emerging Conflicts of Interest?
Frederik H.E. Schagen,1 Rob C. Hoeben,1,2 and Geke A.P. Hospers1,3
Abstract
Recently, the first human medicine containing a genetically modified organism (GMO medicine) was autho-
rized for use in the European market. Just as any medicinal product, the market authorization for a GMO
medicine contains a precise description of the therapeutic use for which the medicinal product is intended.
Within this use, the application of the GMO medicine is permitted, without the need for the institution to obtain
a specific permit. In practice, however, medicinal products are also frequently prescribed for treatment outside
the registered therapeutic use, a practice that is referred to as ‘‘off-label use.’’ While off-label use of con-
ventional medicines is permitted and has been very useful, the off-label use of GMO medicines is not covered in
the European Union (EU) legislation or guidelines and falls under each member state’s national environmental
legislation. This implies that in the Netherlands and most other EU member states, an environmental permit will
be required for any institution that uses the GMO medicine outside the registered application(s). In the
Netherlands, this permit is identical to the permits required for the execution of clinical trials involving
nonregistered GMOs. The application procedure for such permit is time-consuming. This process can therefore
limit the therapeutic options for medical professionals. As a consequence, desired treatment regimens could be
withheld for certain patient (groups). To make future off-label use of GMO medicines permissible in a way that
is acceptable for all stakeholders, regulators should adopt a proactive attitude and formulate transparent leg-
islative procedures for this. Only then the field can maintain the public acceptance of GMO medicines, while
maintaining the freedom to operate of medical professionals.
Introduction
The field of gene therapy is an illustrative example ofa biomedical research field in which the scientific
community has been collaborating productively with regu-
latory authorities in order to develop a rational and reason-
able legislative framework for balancing the risks and
benefits of the new technology. This has led to a broad public
acceptance of the gene therapy field as a viable medical av-
enue along which to seek new treatment strategies for human
disease. In several diseases, evidence of clinical efficacy has
been provided, offering hope of new efficacious treatments
for serious human diseases that so far were incurable.
Recently, the first human medicine consisting of a ge-
netically modified organism (GMO medicine) was autho-
rized for use in the European market. This GMO medicine,
called Glybera, is based on an AAV vector and is developed
to treat lipoprotein lipase deficiency (European Medicines
Agency, 2012; Bryant et al., 2013). Apart from Glybera,
also human vaccines consisting of GMOs, that is, Fluenz
and Fluenz Tetra, obtained market authorization within
Europe. Both GMO vaccines contain GM-influenza viruses
and protect against influenza A and B strains (European
Medicines Agency, 2011, 2013).
The market authorization for a medicinal product contains
a precise description of the therapeutic indications, dosages,
formulations, and patient groups for which the medicinal
product is intended. In practice, however, medicinal products
are frequently prescribed for treatments outside their regis-
tered therapeutic uses, a practice referred to as ‘‘off-label
use.’’ In the European Union (EU), the drug manufacturers
are required to report on the off-label use of their medicinal
products as part of the postmarketing surveillance. Physicians
are, however, not compelled to notify an off-label prescrip-
tion and indicated to be not always aware whether a pre-
scription is off-label or not (Caspers et al., 2007).
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A systematic analysis of the off-label drug use in outpa-
tient care in the United States revealed that on average 21%
of all estimated uses for commonly prescribed medications
are off-label (Radley et al., 2006). But the magnitude of off-
label use varies widely among specific medications and did
exceed 50% for some anticonvulsants, psychiatric medica-
tions, and antiasthmatics. Also, in Europe the off-label use is
assumed to be common practice. The studies performed to
measure its extent focus mainly on the off-label prescription
in children. This group is frequently excluded from the
registered patient groups. Although the reported percentage
off-label use in children is variable, it forms a substantial
part of all prescriptions of a registered medicine and can add
up to 39% (Conroy et al., 2000, 2003; Jong’t et al., 2004;
Leveˆque, 2008). Moreover, a survey of all pediatric uses of
medicinal products in Europe, which was issued by the Eu-
ropean Medicines Agency, reports even higher rates, espe-
cially in case of the drug prescription to prematures, neonates,
and infants (European Medicines Agency, 2010).
About a decade ago, the GMO medicinal products Gen-
dicine and Oncorine were approved by the Chinese State
Food and Drug Administration for use on the Chinese market
(Pearson et al., 2004; Jia, 2006). Both medicinal products
were registered for treatment of head and neck cancer, but are
extensively off-label-prescribed for the treatment of other
tumors, that is, lung cancer, liver cancer, and gastric carci-
nomas (Ma et al., 2009; Kaptein et al., 2010).
Given the fact that off-label use of conventional medi-
cines is generally accepted and practiced, and the GMO
medicines registered in China are widely off-label-
prescribed, it seems highly likely that in Europe GMO
medicines will be used off-label as well.
Market Authorization of a GMO Medicine
Does Not Include Off-Label Use
Before new medicinal products can be authorized for use
in the European market, they are put through an extensive
evaluation by the European Medicines Agency (EMA)
(European Commission, 2006). This evaluation focuses on
pharmaceutical quality, efficacy, and safety in view of and
limited by the proposed therapeutic indications, dosages,
formulations, and patient groups. These are recorded in
detail in the Summary of Product Characteristics when a
medical product is registered (European Commission, 2009).
Besides evaluating conventional medicines for market
registration in the EU, the EMA is also responsible for the
evaluation of market authorization applications for medi-
cines partly or wholly based on GMOs. Apart from the ef-
ficacy and human safety, the environmental safety forms a
key issue in the evaluation of the requested market autho-
rization of a GMO medicinal product (European Medicines
Agency, 2009). To ensure the environmental safety, an ex-
tensive environmental risk assessment is performed, which
is done within the scope of the intended therapeutic use. The
possible off-label uses and linked environmental risks are
not included in the assessment of the market authorization.
Off-label use of GMO medicines is not accounted for in
the EU directives and regulations that are applicable to the
market authorization of GMO medicines (The European
Parliament and the Council of the European Union, 2001a,b,
2004). Just as conventional medicines, the market authori-
zation of a GMO medicine is limited to the registered
therapeutic indications, dosages, formulations, and patient
groups. The assessment and the market authorization does
not cover off-label use of a GMO medicine. So far, EMA
has not issued any guidelines on the off-label prescription of
GMO medicines. Consequently, the off-label use of GMO
medicines falls under the general European GMO legislation
supplemented with each member state’s national environ-
mental legislation on the use of GMOs (The European
Parliament and the Council of the European Union, 2001a,
2009; Perseus, 2006).
In the environmental risk regulations of the Netherlands
and probably of most other member states, the off-label use
of a GMO medicine will be considered similarly to a clinical
trial, with nonregistered GMO medicinal products. Depen-
dent on the EU member state, this implies that a medical
center should apply for a permit for contained use, deliberate
release, or, in some countries, for a specific gene therapy trial
permit, before starting the off-label use of a GMO medicine
(Perseus, 2006).
Prerequisites for Off-Label Use of a GMO Medicine
in the Netherlands
Under the Dutch environmental legislation, off-label use
of a registered GMO medicine is considered as a deliberate
release into the environment. Consequently, the prescription
of a GMO medicine for nonregistered therapeutic indica-
tions requires a permit for the deliberate release of a GMO
into the environment. Such a permit application involves the
assembly of a large portfolio of information about the GMO
and the biosafety aspects of the study in accordance with the
European directive for deliberate release of a GMO into
the environment (The European Parliament and the Council
of the European Union, 2001a). This includes an assessment
of the possibility and impact of dispersal of the GMO and
infection of third parties. Also, the potential occurrence of
new GMOs as a result of interaction of the GMO medicine
with naturally occurring microorganisms is assessed. De-
pendent on the outcome of the performed environmental risk
assessment, the application should identify necessary risk
management measures such as containment measures to
minimize possible environmental risks.
In the Netherlands, the whole procedure for evaluating
the application takes at least 5 months, and longer if the
process is interrupted to collect further information or if
objections are lodged against issuing the permit during the
6-week period of public consultation (Gene Therapy Office,
2013). Although the permit required for a clinical trial
with GMO medicinal products and the procedure followed
will differ between the EU member states, the permit ap-
plication is in general a time-consuming and labor-intensive
procedure.
Conflicts of Interest
The off-label prescription of conventional medicines is
legally allowed and a common practice in healthcare to date.
Dependent on the medicine and its registered therapeutic
indication, off-label use can form a substantial share of the
total prescription of a medicine. Key criteria for off-label
use are a thorough scientific evidence base and the lack of a
registered alternative. In practice, off-label prescription is
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based on the professional responsibility and the legal obliga-
tion of the physician to give the patient an optimal treatment.
If off-label prescriptions were prohibited, physicians would
be limited in their freedom to offer suitable care to their pa-
tients. It would deny patients access to desired treatment, and
‘‘special’’ patients, such as children, elderly, pregnant women,
and patients with rare diseases, would be left without access to
suitable medicines. Off-label use of medicines is therefore
essential to provide optimal care to all patients.
On the other hand, we should keep in mind that the in-
terests of the population and the environment are of more
importance than those of a relative limited group of patients.
In case of the use of GMOs, this requires a careful assess-
ment of the potential impact that the GMOs can have on the
environment. Only in this way the environmental risks of
the use of GMO medicines can be limited to an acceptable
level. However, the relatively lengthy procedure of the en-
vironmental permit application may be inhibitive for an off-
label prescription. Moreover, since the permits are restricted
to a single institution, each hospital needs to repeat the
application, even if the off-label use is exactly the same.
The professional responsibility and the obligation of
physicians to provide optimal care will put the physician in
a dilemma. The physician will be forced to balance the in-
terests of the patient on the one hand, and the interest of the
population and the environment on the other. With the re-
cent registration of the first GMO medicine and the GMO
vaccines in Europe, the physicians can be faced with this
dilemma anytime now.
Quo Vadis?
Although the legislative requirements for the off-label
prescription of GMO medicines are clear, they do not do
justice to the emerging conflicts of interest. In fact, irrespec-
tive of the situation, a physician is legally bound to obtain an
environmental permit before any off-label use of GMO
medicines is allowed. The question is whether each physician
is willing to obey this requirement when there seems to be no
eminent environmental risks, and abstain from the obligation
to offer the patients the optimal treatment choice.
The Netherlands Commission on Genetic Modification
highlighted the possible conflicts of interest in case of the
off-label use of GMO medicines already in 2009 (Nether-
lands Commission on Genetic Modification, 2009). Since
then, the first GMO medicine has entered the European
market making off-label use of GMO medicines a matter of
time. So far, the legislative requirements for this type of off-
label prescription remained unchanged, and we have seen no
actions being taken to remedy the emerging conflicts of in-
terest. Whereas these conflicts of interest are complex, a
balanced solution is required that should meet the interests
of the patients, the physicians, and the environment.
One possibility to cope with this issue is to expand the
environmental risk assessment beyond the scope of the
market authorization application by including, for example,
a limited but obvious group of off-label prescriptions in the
environmental risk assessment. As part of the assessment of
the market authorization application, it could be indicated
whether certain off-label uses involve environmental risks
comparable with the intended, to be registered use, or entail
higher environmental risks. In view of the safety for humans
(excluding the patient) and the environment, the first cate-
gory of off-label uses could be made eligible for a fast-track
procedure for issuing the required environmental permit, or
even make such a permit no longer mandatory for this
category of off-label uses. Obviously, this demands an ad-
justment of the national and/or European legislation.
Another possibility would be a national central registra-
tion of the off-label use of GMO medicines. A central da-
tabase could give the medical professionals a detailed
insight in previously applied off-label uses of GMO medi-
cines. If the intended off-label use has been assessed, there
would be no need to repeat this assessment and this should
clear the way for a fast-track permit procedure. Moreover, a
centralized database would also enable a physician to for-
ward the patient to the hospital with the required permit or
to apply for a copy of the permit. This last option is already
allowed in the current legislation. In this case, the remaining
procedure of evaluating the application remains, however,
the same. Obviously, a European-wide central registration
could streamline this option even further, but this will only
work if the member states conform with a uniform envi-
ronmental permit for the off-label use of GMO medicines.
Either way, policymakers of involved ministries have to
deliberate in close consultation with stakeholders on the
practicable policy options and come to a solution that best
meet the various interests. If not, it is inevitable that with the
off-label use of GMO medicines either the patient interest or
the interests of humans and the environment will be jeopar-
dized with all that that entails. In view of the prevailing public
opinion on GMOs, it goes without saying that this issue needs
the required attention and possible legislative adjustments be-
fore the physician is confronted with the illustrated dilemma.
Conclusion
Just as with conventional medicines, it is to be expected that
GMO medicines can be prescribed outside their registered
therapeutic scope. Thismight place themedical professional in
a dilemma with the patient interest on the one hand, and the
public interests of human health and the environment on the
other. To ensure that both interests are best served, the regu-
lations need to be adapted in anticipation of the off-label use of
GMOmedicinal products. If not, the full potential of particular
GMO medicines will probably not be exploited and, even
worse, might be exploited without proper notification and
without a proper environmental risk assessment. In view of the
general public perception on GMOs in Europe, the last sce-
nario is risky and may in fact jeopardize the public opinion and
acceptance of GMO medicines in general.
This calls for a solution that is fully supported and ac-
knowledged by the medical professionals and might en-
compass a simplified and accelerated procedure when the
environmental risks have been assessed before. With the
authorization of the first GMO medicines to the European
market, the off-label prescription of this type of medicines
becomes a matter of time. Hopefully, policymakers can be
incited to address this issue in a timely manner.
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